Modulating potency: Physicochemical characteristics are a determining factor of TLR4-agonist nanosuspension activity

Journal of Pharmaceutical Sciences

Volumn 103, Issue 3, 2014, Pages 879-889

  Dowling, Quinton M ^a   Sivananthan, Sandra J ^a   Guderian, Jeff A ^a   Moutaftsi, Magdalini ^a   Chesko, James D ^a   Fox, Christopher B ^a   Vedvick, Thomas S ^a   Kramer, Ryan M ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

adjuvant; endotoxin; FTIR; glucopyranosyl lipid adjuvant (GLA); in vitro bioactivity; nanoparticle; phospholipid; physicochemical characterization; Toll like receptors (TLR); vaccine development

Indexed keywords

DIPALMITOYLPHOSPHATIDYLCHOLINE; ENDOTOXIN; EXCIPIENT; GLUCOPYRANOSYL LIPID ADJUVANT; IMMUNOLOGICAL ADJUVANT; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; CYTOKINE; DISACCHARIDE; DRUG COMBINATION; LIPID A; MYRISTIC ACID DERIVATIVE; NANOMATERIAL; SUSPENSION; TLR4 PROTEIN, HUMAN;

ARTICLE; BIOLOGICAL ACTIVITY; BLOOD; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG DETERMINATION; DRUG POTENCY; HUMAN; IN VITRO STUDY; LIMULUS LYSATE TEST; MODULATION; NANOSUSPENSION; PARTICLE SIZE; PHYSICAL CHEMISTRY; SPECTROSCOPY; STIMULATION; SURFACE CHARGE; SUSPENSION; ACYLATION; AGONISTS; ANALOGS AND DERIVATIVES; BLOOD CELL; CHEMISTRY; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; IMMUNOLOGY; INTERFERON GAMMA RELEASE ASSAY; METABOLISM; OSMOLARITY; PHOSPHORYLATION; SURFACE PROPERTY; TRANSITION TEMPERATURE;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ACYLATION; ADJUVANTS, IMMUNOLOGIC; BLOOD CELLS; CYTOKINES; DISACCHARIDES; DRUG COMBINATIONS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LIPID A; MYRISTATES; NANOSTRUCTURES; OSMOLAR CONCENTRATION; PARTICLE SIZE; PHOSPHORYLATION; PHYSICOCHEMICAL PHENOMENA; SURFACE PROPERTIES; SUSPENSIONS; TOLL-LIKE RECEPTOR 4; TRANSITION TEMPERATURE;

EID: 84894456418     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23868     Document Type: Article

References (44)

1. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R,. 2010. New adjuvants for human vaccines. Curr Opin Immunol 22 (3): 411-416.
2. De Gregorio E, D'Oro U, Wack A,. 2009. Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol 21 (3): 339-345.
3. Kawai T, Akira S,. 2005. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 17 (4): 338-344.
4. Fox CB, Haensler J,. 2013. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines 12 (7): 747-758.
5. Miyake K., 2006. Roles for accessory molecules in microbial recognition by Toll-like receptors. J Endotox Res 12 (4): 195-204.
6. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ,. 1990. Structure and function of lipopolysaccharide binding protein. Science 249 (4975): 1429-1431.
7. Tobias PS, Soldau K, Gegner JA, Mintz D, Ulevitch RJ,. 1995. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem 270 (18): 10482-10488.
8. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC,. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249 (4975): 1431-1433.
9. Brandenburg K, Matsuura M, Heine H, Muller M, Kiso M, Ishida H, Koch MH, Seydel U,. 2002. Biophysical characterization of triacyl monosaccharide lipid a partial structures in relation to bioactivity. Biophys J 83 (1): 322-333.
10. Brandenburg K, Wagner F, Müller M, Heine H, Andrä J, Koch MHJ, Zähringer U, Seydel U,. 2003. Physicochemical characterization and biological activity of a glycoglycerolipid from Mycoplasma fermentans. Eur J Biochem 270 (15): 3271-3279.
11. Seydel U, Oikawa M, Fukase K, Kusumoto S, Brandenburg K,. 2000. Intrinsic conformation of lipid A is responsible for agonistic and antagonistic activity. Eur J Biochem/FEBS 267 (10): 3032-3039.
12. Kerth A, Garidel P, Howe J, Alexander C, Mach JP, Waelli T, Blume A, Th Rietschel E, Brandenburg K,. 2009. An infrared reflection-absorption spectroscopic (IRRAS) study of the interaction of lipid A and lipopolysaccharide Re with endotoxin-binding proteins. Med Chem 5 (6): 535-542.
13. Anderson RC, Fox CB, Dutill TS, Shaverdian N, Evers TL, Poshusta GR, Chesko J, Coler RN, Friede M, Reed SG, Vedvick TS,. 2010. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B: Biointerfaces 75 (1): 123-132.
14. Arias MA, Van Roey GA, Tregoning JS, Moutaftsi M, Coler RN, Windish HP, Reed SG, Carter D, Shattock RJ,. 2012. Glucopyranosyl lipid adjuvant (GLA), a synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PloS One 7 (7): e41144.
15. Baldwin SL, Bertholet S, Reese VA, Ching LK, Reed SG, Coler RN,. 2012. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol 188 (5): 2189-2197.
16. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, Laughlin EM, Duthie MS, Fox CB, Carter D, Friede M, Vedvick TS, Reed SG,. 2011. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PloS One 6 (1): e16333.
17. Orr MT, Fox CB, Baldwin SL, Sivananthan SJ, Lucas E, Lin S, Phan T, Moon JJ, Vedvick TS, Reed SG, Coler RN,. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release 172 (1): 190-200.
18. Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS,. 2012. Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions. AAPS PharmSciTech. 13 (2): 498-506.
19. O'Hagan DT, Ott GS, De Gregorio E, Seubert A,. 2012. The mechanism of action of MF59-An innately attractive adjuvant formulation. Vaccine 30 (29): 4341-4348.
20. McClements DJ,. 2007. Critical review of techniques and methodologies for characterization of emulsion stability. Crit Rev Food Sci Nutr 47 (7): 611-649.
21. Brumm T, Jørgensen K, Mouritsen OG, Bayerl TM,. 1996. The effect of increasing membrane curvature on the phase transition and mixing behavior of a dimyristoyl-sn-glycero-3-phosphatidylcholine/ distearoyl-sn-glycero-3- phosphatidylcholine lipid mixture as studied by Fourier transform infrared spectroscopy and differential scanning calorimetry. Biophys J 70 (3): 1373-1379.
22. Brewer JM, Pollock KG, Tetley L, Russell DG,. 2004. Vesicle size influences the trafficking, processing, and presentation of antigens in lipid vesicles. J Immunol 173 (10): 6143-6150.
23. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA,. 2008. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci 105 (38): 14265-14270.
24. Fox CB, Kramer RM, Barnes V L, Dowling QM, Vedvick TS,. 2013. Working together: Interactions between vaccine antigens and adjuvants. Ther Adv Vaccines 1 (1): 7-20.
25. Bajoria R, Sooranna SR, Contractor SF,. 1997. Endocytotic uptake of small unilamellar liposomes by human trophoblast cells in culture. Hum Reprod 12 (6): 1343-1348.
26. Lee K-D, Hong K, Papahadjopoulos D,. 1992. Recognition of liposomes by cells: In vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim Biophys Acta 1103 (2): 185-197.
27. Howe J, Andrä J, Conde R, Iriarte M, Garidel P, Koch MHJ, Gutsmann T, Moriyõn I, Brandenburg K,. 2007. Thermodynamic analysis of the lipopolysaccharide-dependent resistance of Gram-negative bacteria against polymyxin B. Biophys J 92 (8): 2796-2805.
28. Yellin N, Levin IW,. 1977. Hydrocarbon chain trans-gauche isomerization in phospholipid bilayer gel assemblies. Biochemistry 16 (4): 642-647.
29. Lewis RN, Pohle W, McElhaney RN,. 1996. The interfacial structure of phospholipid bilayers: Differential scanning calorimetry and Fourier transform infrared spectroscopic studies of 1,2-dipalmitoyl-sn-glycero-3-phosphorylcholine and its dialkyl and acyl-alkyl analogs. Biophys J 70 (6): 2736-2746.
30. Nagarajan S, Schuler EE, Ma K, Kindt JT, Dyer RB,. 2012. Dynamics of the gel to fluid phase transformation in unilamellar DPPC vesicles. J Phys Chem B 116 (46): 13749-13756.
31. Foged C, Brodin B, Frokjaer S, Sundblad A,. 2005. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 298 (2): 315-322.
32. Hubbell JA, Thomas SN, Swartz MA,. 2009. Materials engineering for immunomodulation. Nature 462 (7272): 449-460.
33. Makino K, Yamada T, Kimura M, Oka T, Ohshima H, Kondo T,. 1991. Temperature- and ionic strength-induced conformational changes in the lipid head group region of liposomes as suggested by zeta potential data. Biophys Chem 41 (2): 175-183.
34. Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS,. 2012. Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions. AAPS PharmSciTech 13 (2): 498-506.
35. Chen X, Howe J, Andrä J, Rössle M, Richter W, da Silva APG, Krensky AM, Clayberger C, Brandenburg K,. 2007. Biophysical analysis of the interaction of granulysin-derived peptides with enterobacterial endotoxins. Biochim Biophys Acta 1768 (10): 2421-2431.
36. Takayama K, Mitchell DH, Din ZZ, Mukerjee P, Li C, Coleman DL,. 1994. Monomeric Re lipopolysaccharide from Escherichia coli is more active than the aggregated form in the Limulus amebocyte lysate assay and in inducing Egr-1 mRNA in murine peritoneal macrophages. J Biol Chem 269 (3): 2241-2244.
37. Mittal N, Sanyal SN,. 2010. Intratracheal instillation of surfactant inhibits lipopolysaccharide-induced acute respiratory distress syndrome in rats. Am J Biomed Sci 2: 190-201.
38. Xu ZC, Cafiso DS,. 1986. Phospholipid packing and conformation in small vesicles revealed by two-dimensional 1H nuclear magnetic resonance cross-relaxation spectroscopy. Biophys J 49 (3): 779-783.
39. Nagarajan S, Schuler EE, Ma K, Kindt JT, Dyer RB,. 2012. Dynamics of the gel to fluid phase transformation in unilamellar DPPC vesicles. J Phys Chem B 116 (46): 13749-13756.
40. Gutsmann T, Howe J, Zahringer U, Garidel P, Schromm AB, Koch MH, Fujimoto Y, Fukase K, Moriyon I, Martinez-de-Tejada G, Brandenburg K,. 2010. Structural prerequisites for endotoxic activity in the Limulus test as compared to cytokine production in mononuclear cells. Innate Immun 16 (1): 39-47.
41. Akashi S, Ogata H, Kirikae F, Kirikae T, Kawasaki K, Nishijima M, Shimazu R, Nagai Y, Fukudome K, Kimoto M,. 2000. Regulatory roles for CD14 and phosphatidylinositol in the signaling via toll-like receptor 4-MD-2. Biochem Biophys Res Commun 268 (1): 172-177.
42. Poltorak A, He X, Smirnova I, Liu M-Y, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B,. 1998. Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282 (5396): 2085-2088.
43. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M,. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189 (11): 1777-1782.
44. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC,. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249 (4975): 1431-1433.